Print this page
Back to Web version of article
Index of Articles From 1995 TAGlines
- December, 1995
- CMV's Real World
When Two Prophylaxis Studies Declare Opposite Findings, Clinicians And Their Patients Are Lost in the Quandary - A question of patient management
- Giving Away the Farm
How Corporate Cynicism, Savvy Schmoozing and Relentless PR Paved The Way to Unqualified Approval for Two New Antiretrovirals - "Grave disservice to the public health"
- Random Gleanings
Tracking down the elusive CD8 cell factor, FDA panel recommends approval for ganciclovir implant, FDA approval for saquinavir; Lottery for ritonavir
- Subsctiption Information
- November, 1995
- Antiretroviral Horizon
35th Interscience Conference Unveils Results from Several Important Clinical Studies - Protease and paradox
- I'll Take Los Angeles
AIDS Treatment Activists from Across the Land Gather to Share Expertise and Ideas - "A conversation long overdue"
- Random Gleanings
FDA Antiviral Drugs Advisory Committee, Ambushed in the FDCs, Expanding T cells: Koenig weighs in on Good CTLs/Bad CTLs debate
- October, 1995
- "Kiss My Access"
Community Envoy to Food and Drug Panel Urges Caution in Approving New Anti-HIV Therapueutics and in Providing Early Access - "Badgering, hijacking activists"
- Reversal of Fortune
Despite Pressure to Crown Combo King, 175 Investigators Soft-Pedal Combination Nucleoside Study's Startling Findings - The didanosine surprise
- Washington Woes
Senate Appropriations Committee, the OAR's blue-ribbon review of the NIH AIDS program, TAG's Gregg Gonsalves, AmFAR Public Policy Director Jane Silver
- Conclusions for ACTG 175
- September, 1995
- August, 1995
- Science South of the Border
Feel Good Merck Meeting Leaves Everybody Agreeing, But Brazil Study Bodes Ill for the Future - Wrangling over control arm
- Diversity Threshold
New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome - Sloppy RT, Bane of All
- April, 1995
- Integrase: The Next Viral Target
With Two Down And Integrase On Deck, AIDS Research Team Hopes For a Hit--Or Will It Be 'Three Up, Three Down?'
- The Doxil NDA
FDA's Oncological Drug Advisory Committee Recommends DOX-SL for Accelerated Approval--But Not Without A Fight
- March, 1995
- Random Gleanings
FDA Just Says "No" To Salk Immunogen, Heralding the Naked Emperor (Part II), OAR's Dr. Paul Speaks, Varmus Selects New Director for Office of Alternative Medicine
- Dr. Emini's Gamble
Merck's Scientists Cave In To The Vogue of Surrogate Marker Endpoint Trials, Accelerated Approval And Quick Cash
- Souped-Up Abs from LTNPs
Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for "Bad" Cytokines; Parke-Davis Targets Cellular Factors
- February, 1995
- The CTL As Both Villain and Victor
Fascinating Work on HIV and T-Cell Kinetics Challenges Longtime Dismissal of Ravaged Immune System's Regenerative Potential
- Re-Inventing Government
New ACTG Structure Squeezes Eleven Committees Into Three--But Will Anything Really Be Any Different?
- Hope for Sale
Like the Wings of Icarus, Treatment Hype Sweeps Its prey Upward to the Heavens, Then Plucks Them Down Into icey Waters
- January, 1995
Back to the Treatment Action Group index page
You can find this article online by typing this address into your Web browser:
General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.